Akebia Therapeutics Secures Up to $140 Million in New Financing, Eliminates BlackRock Debt and Strengthens Kidney Disease Strategy 

Akebia Therapeutics, a Massachusetts-based biopharmaceutical company specializing in kidney disease treatments, has announced a new financing agreement designed to strengthen its financial flexibility and support future business development.

The company secured a $60 million senior secured loan from healthcare investment firm Symbiotic Capital, replacing an existing $55 million debt facility associated with BlackRock.

Announced on November 16, 2026, the agreement provides access to as much as $140 million in total financing, although additional funding remains subject to lender approval. The transaction represents an important financial restructuring as Akebia continues developing and commercializing treatments for patients with kidney disease.

The new loan facility closed on November 12, with Symbiotic Capital immediately providing $60 million. Akebia used the proceeds to repay its previous $55 million loan in full, ending that borrowing arrangement.

After financing fees and related expenses, the company received approximately $58.6 million in net proceeds. The agreement also allows Akebia to request up to $80 million in additional financing.

However, that money is not guaranteed. Symbiotic Capital retains discretion over whether to approve and fund future borrowing requests. This distinction is important because the company has secured $60 million, rather than receiving the entire $140 million immediately.

The financing arrangement carries a five-year maturity, with repayment scheduled for November 12, 2031. During that period, Akebia is required to make interest payments but does not face scheduled principal repayments.

The full principal balance becomes due at maturity unless the company repays or refinances it earlier. Interest is calculated using a variable annual rate equal to the greater of 11.5% or the Wall Street Journal prime rate plus 4.5 percentage points, subject to a 15% ceiling.

While the structure provides flexibility, it also creates ongoing borrowing costs. The loan is secured by substantially all qualifying assets of Akebia and its participating subsidiaries.

Founded in 2007 and headquartered in Waltham, Massachusetts, Akebia focuses on developing and commercializing therapies for patients affected by kidney disease. Its business includes revenue-generating medicines and a pipeline of potential treatments.

The company markets Vafseo, a medication associated with treating anemia in certain patients with chronic kidney disease. Developing and commercializing pharmaceutical products requires substantial investment in clinical research, manufacturing, regulatory compliance and distribution.

The new financing could help Akebia manage these expenses while pursuing its broader commercial objectives. However, the company has not announced that the transaction will fund a specific new clinical trial or product launch.

Erik Ostrowski, Akebia’s chief financial and business officer, said the financing improves operational flexibility and creates the possibility of accessing additional capital without immediately issuing new shares.

Management also reaffirmed its expectation of having sufficient cash to fund operations for at least two years. Symbiotic Capital expressed confidence in Akebia’s existing product portfolio, kidney disease pipeline and experienced management team.

The agreement may improve Akebia’s ability to manage debt obligations and pursue strategic initiatives. Nevertheless, refinancing does not eliminate the company’s indebtedness. Investors must consider interest expenses, future repayment requirements and the conditions attached to additional borrowing. Akebia also issued warrants to the lender, creating potential future shareholder dilution if exercised.